Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $7.8 million.

  • Altimmune's Accumulated Expenses rose 395.74% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 395.74%. This contributed to the annual value of $10.3 million for FY2024, which is 182.67% up from last year.
  • Per Altimmune's latest filing, its Accumulated Expenses stood at $7.8 million for Q3 2025, which was up 395.74% from $8.4 million recorded in Q2 2025.
  • Altimmune's Accumulated Expenses' 5-year high stood at $19.1 million during Q3 2021, with a 5-year trough of $7.4 million in Q2 2023.
  • In the last 5 years, Altimmune's Accumulated Expenses had a median value of $9.7 million in 2023 and averaged $10.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 25286.03% in 2021, then crashed by 3838.58% in 2023.
  • Altimmune's Accumulated Expenses (Quarter) stood at $10.2 million in 2021, then rose by 20.67% to $12.2 million in 2022, then dropped by 17.77% to $10.1 million in 2023, then rose by 1.83% to $10.3 million in 2024, then dropped by 23.93% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $8.4 million for Q2 2025, and $8.7 million during Q1 2025.